Drugs / YH004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05564806 | Jan 2023 → Oct 2025 | cancer, non-Hodgkin lymphoma | Eucure (Beijing) Biopharma Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT05040932 | Dec 2021 → Jul 2023 | cancer | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YH004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05564806 ↗ |
| Action | Activate | “acts as an agonist against 4-1BB” NCT05040932 ↗ |
| Modality | Monoclonal antibody | “YH004 is a humanized monoclonal antibody” NCT05040932 ↗ |
| Route | Intravenous | “Route of administration is IV infusion” NCT05040932 ↗ |